Office Locations:

50 Milk Street, 16th Floor
Boston, MA 02109
Phone: (617) 634-2318



  • Early



  • Life Sciences & Healthcare
  • Medical Device



    JDRF T1D Fund is an independently managed venture philanthropy fund that will make early-stage commercial investments to accelerate life-changing type 1 diabetes (T1D) therapies. The JDRF T1D Fund will make high-impact early-stage investments to accelerate commercial development of life-changing therapies for people living with T1D. The fund is the first vehicle devoted to early-stage commercial investing in T1D; over $65 million raised to date. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, with an exclusive focus on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission. The Fund has $70 million in assets under management with 13 portfoilio companies.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Katie Ellias Managing Director
    Yury Kukushkin Investment Director


    Recent Funding Events (trailing 12 months):







      SQZ Biotech



      Series D


      i2O Therapeutics





      Pandion Therapeutics



      Series B


      IM Therapeutics



      Series A


    Portfolio companies include:


    Recent News: